Comparing Innovation Spending: Takeda Pharmaceutical Company Limited and Geron Corporation

Takeda vs. Geron: A Decade of R&D Investment

__timestampGeron CorporationTakeda Pharmaceutical Company Limited
Wednesday, January 1, 201420707000382096000000
Thursday, January 1, 201517831000345927000000
Friday, January 1, 201618047000312303000000
Sunday, January 1, 201711033000325441000000
Monday, January 1, 201813432000368298000000
Tuesday, January 1, 201952072000492381000000
Wednesday, January 1, 202051488000455833000000
Friday, January 1, 202185727000526087000000
Saturday, January 1, 202295518000633325000000
Sunday, January 1, 2023125046000729924000000
Monday, January 1, 2024729924000000
Loading chart...

Data in motion

A Tale of Two Innovators: Takeda vs. Geron

In the ever-evolving landscape of pharmaceutical innovation, research and development (R&D) spending is a key indicator of a company's commitment to future breakthroughs. Over the past decade, Takeda Pharmaceutical Company Limited and Geron Corporation have demonstrated contrasting approaches to R&D investment.

From 2014 to 2023, Takeda's R&D expenses have surged by approximately 91%, reflecting its robust strategy to maintain a competitive edge in the global market. In contrast, Geron Corporation, a smaller player, has increased its R&D spending by nearly 504% during the same period, showcasing its aggressive push towards innovation despite its limited resources.

While Takeda's R&D budget dwarfs Geron's, the latter's rapid growth in spending underscores its determination to carve out a niche in the industry. As we look to the future, these trends highlight the diverse strategies companies employ to drive innovation and secure their place in the pharmaceutical sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025